Relay Therapeutics Announces Data From Phase 1/2 ReDiscover Trial Of Zovegalisib + Fulvestrant At Phase III Recommended Dose; Data To Be Presented At European Society for Medical Oncology (ESMO) Targeted Anticancer Therapies (TAT) Congress 2026 In Paris, France.